Alira Health

Alligator-Derived Hyaluronic Acid: Bacteriostatic and Fungastatic Properties Against Pathogens

Non-healing wounds are often stalled in the inflammatory phase and considered hard-to-heal or chronic wounds when healing is delayed for over 4 weeks, and up to more than three months. The longer it takes these wounds to heal poses a severe risk for a polymicrobial infection which can stall the wound even further in the inflammatory phase and is concomitant with a higher incidence of lower extremity amputation and mortality.

Scientific Articles
Published on:
January 26, 2023
Considering that alligator tissues have been found to have bacteriostatic and fungistatic properties, it is possible that alligator-derived hyaluronic acid may play a critical role in reducing the bioburden to promote chronic wound healing."

Hyaluronic acid has been utilized in wound care to replenish and stabilize the extracellular matrix in a chronic wound bed. Hyaluronic acid has also been shown to protect stem cells, growth factors, and cytokines required for cell proliferation and angiogenesis. Considering that alligator tissues have been found to have bacteriostatic and fungistatic properties, it is possible that alligator-derived hyaluronic acid may play a critical role in reducing the bioburden to promote chronic wound healing.

In the paper “Alligator-Derived Hyaluronic Acid: Bacteriostatic and Fungastatic Properties Against Pathogens” published in Wound Masterclass journal, our Product Development Laboratory team worked with Dr. Swathi Balaji of Texas Children’s Hospital, Dr. Thomas Serena of SerenaGroup, and Ted Bundrick of Lacerta Life Sciences, to provide evidence that alligator-derived hyaluronic acid can act on the inflammatory phase of wound healing.

The list of Alira Health’s contributors include:

  • Mitch Sanders, PhD, Chief Scientific Officer
  • Mia Hanna, Research Associate III, Project Manager
  • Vanessa Vu, Research Associate I
  • Lindsay Poland, Scientist III, Lab Operations Mgr.

The paper “Alligator-Derived Hyaluronic Acid: Bacteriostatic and Fungastatic Properties Against Pathogens” is available on page 60 of Volume 1: Issue 3 (December 2022) of Wound Masterclass.

Related news

Articles March 27, 2025
Tangible Ways Patient Insights Accelerate Access and Product Launch
This article explores how leveraging patient insights can help companies overcome market access barriers and improve their chances of success.
Patient Centricity Patient Engagement Patient-Enabled Innovation Product Development
Events April 20, 2024
Symposium on Advanced Wound Care Spring 2025
Connect onsite with CEO Gabriele Brambilla and SVP of Clinical Operations Chris Rao to learn what Alira Health brings to advanced wound care.
Diabetes Research & Development Wound Healing
News March 27, 2024
Alira Health Joins Forces with APMA to Advance Podiatric Registry
Alira Health joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and(...)
Real-World Evidence (RWE) Registry-based studies Research and Development Wound Healing
Events March 13, 2024
EWMA 2024
Meet us at the 34th EWMA Conference to learn about our expertise in the wound care market in both acute and non-acute care settings.
Wound Healing
Articles March 13, 2024
Strategic Patient Engagement as a Game Changer for Your Product Success
This FAQ addresses popular questions about how to make patient engagement the core of a product development and commercialization strategy.
Patient Centricity Patient Engagement Product Development
Scientific Articles November 14, 2023
Pressure Ulcer Prevention Devices in the Management of Older Patients at Risk After Hospital Discharge: an SNDS Study
Our team explores the effectiveness of Pressure Ulcer Prevention Devices (PUPDs) for at-risk patients following hospital discharge in France.
Diabetes Real-World Evidence (RWE) Wound Healing
News October 18, 2023
Alira Health’s CDD Supports TVM Capital Healthcare Investment in DEBx Medical
Following Alira Health’s Commercial Due Diligence (CDD), TVM Capital Healthcare has completed a multi-million euro investment in DEBx Medical.
CDD Medical Devices Wound Healing
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.